SAN DIEGO, Feb. 2, 2016 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver corporate presentations at two upcoming investor conferences in New York. Dr. Lian will present at the 18th BIO CEO & Investor Conference, being held February 8-9, 2016, and the Source Capital Group 2016 Disruptive Growth & Healthcare Conference, being held in February 10, 2016.
Details of these presentations are as follows:
- 18th BIO CEO & Investor Conference 2016
Time/Date: 5:30 p.m. ET on Monday, February 8, 2016
Location: The Waldorf Astoria New York
Room: Park North
Track: Metabolic Diseases
- Source Capital Group 2016 Disruptive Growth & Healthcare Conference
Time/Date: Noon ET on Wednesday, February 10, 2016
Location: Convene Conference Center @ 730 Third Ave, New York
Room: Track 1 – Tribeca Hub
To access the live webcast of Viking's BIO CEO & Investor Conference presentation, please visit "Webcasts & Presentations" within the News & Events section of Viking's Investors page at www.vikingtherapeutics.com. Additionally, a replay of the webcast will be available on the Viking website following the conference.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. The company's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals, Inc. The company's clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, in Phase 2 development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery, VK2809, a small molecule thyroid beta agonist entering Phase 2 development for hypercholesterolemia and fatty liver disease, and VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes. Viking is also developing novel and selective agonists of the thyroid beta receptor for adrenoleukodystrophy, as well as two earlier-stage programs targeting metabolic diseases and anemia.
SOURCE Viking Therapeutics, Inc